Maravai LifeSciences
MRVI
212 hedge funds and large institutions have $1.81B invested in Maravai LifeSciences in 2022 Q4 according to their latest regulatory filings, with 58 funds opening new positions, 93 increasing their positions, 50 reducing their positions, and 45 closing their positions.
86% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 50
29% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 45
5% more funds holding
Funds holding: 202 → 212 (+10)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.08% less ownership
Funds ownership: 99.4% → 96.32% (-3.1%)
30% less call options, than puts
Call options by funds: $934K | Put options by funds: $1.34M
46% less capital invested
Capital invested by funds: $3.34B → $1.81B (-$1.53B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$57M |
| 2 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$32.6M |
| 3 |
Renaissance Technologies
New York
|
+$28.4M |
| 4 |
Jennison Associates
New York
|
+$22.6M |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$18.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Select Equity Group
New York
|
-$219M |
| 2 |
AIM
Artemis Investment Management
Edinburgh,
United Kingdom
|
-$63.3M |
| 3 |
UBS AM
Chicago,
Illinois
|
-$55M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$38.3M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$24.3M |
MRVI Hedge Fund Activity: Q4 2022 in Review
212 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Maravai LifeSciences (MRVI) for Q4 2022, worth a combined $1.81B — down 46% from $3.34B a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new MRVI positions and 45 closed out — a net gain of 13 holders — while 93 added to existing stakes and 50 trimmed.
The largest buyer was Thrivent Financial for Lutherans, adding an estimated $57M. The largest seller was Select Equity Group, cutting an estimated $219M.
- 212 institutional investors held Maravai LifeSciences (MRVI) as of Q4 2022, up from 202 in Q3 2022.
- Funds reported $1.81B of Maravai LifeSciences stock for Q4 2022, down 46% quarter-over-quarter.
- 58 funds opened new Maravai LifeSciences positions in Q4 2022 and 45 closed out, a net change of +13 holders.
- The largest Maravai LifeSciences buyer in Q4 2022 was Thrivent Financial for Lutherans, an estimated $57M added.
- The largest Maravai LifeSciences seller in Q4 2022 was Select Equity Group, an estimated $219M sold.
Based on aggregated 13F filings for Q4 2022.